SUBSCRIBE
SUBSCRIBE

Actuate Therapeutics

NEWS
Drug Development
Clinical Catch-Up: Covaxin, Celyad Hold, CRISPR’s Next Step
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
March 4, 2022
 · 
8 min read
 · 
Mark Terry
Deals
Actuate Therapeutics Completes $6.5 Million Series B-3 Financing To Expand Clinical Programs
Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, announced it has raised an additional $6.5M in a Series B-3 financing round.
November 12, 2019
 · 
4 min read
Lone Star Bio
Actuate Therapeutics Secures $21.7 Million to Support Phase I/II Clinical Trial
The company took its GSK-3B inhibitor into the clinic earlier this year. The drug is being studied in patients with refractory hematologic malignancies or solid tumors.
May 17, 2019
 · 
2 min read
 · 
Alex Keown
JOBS
IN THE PRESS
Press Releases
Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor
September 23, 2024
 · 
6 min read
Press Releases
Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas
September 11, 2024
 · 
6 min read
Press Releases
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma
September 9, 2024
 · 
7 min read
Press Releases
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 5, 2024
 · 
1 min read
Business
Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024
August 20, 2024
 · 
3 min read
Press Releases
Actuate Therapeutics Announces Closing of Initial Public Offering
August 15, 2024
 · 
4 min read
Business
Actuate Therapeutics Announces Pricing of Initial Public Offering
August 12, 2024
 · 
4 min read
Deals
Actuate Therapeutics Files Registration Statement for Initial Public Offering
May 28, 2024
 · 
2 min read
BioMidwest
Actuate Therapeutics Announces Poster Presentations at the 2024 AACR Annual Meeting
April 8, 2024
 · 
1 min read
Policy
Actuate Therapeutics Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Pancreatic Cancer
August 1, 2023
 · 
2 min read
Load More